CL2007002620A1 - Compuesto marcado con isotopo de fluor; metodo para preparar dicho compuesto; composicion que comprende dicho compuesto; metodo de tomar imagenes de enfermedades que comprende el compuesto antes mencionado; kit que comprende dicho compuesto. - Google Patents

Compuesto marcado con isotopo de fluor; metodo para preparar dicho compuesto; composicion que comprende dicho compuesto; metodo de tomar imagenes de enfermedades que comprende el compuesto antes mencionado; kit que comprende dicho compuesto.

Info

Publication number
CL2007002620A1
CL2007002620A1 CL200702620A CL2007002620A CL2007002620A1 CL 2007002620 A1 CL2007002620 A1 CL 2007002620A1 CL 200702620 A CL200702620 A CL 200702620A CL 2007002620 A CL2007002620 A CL 2007002620A CL 2007002620 A1 CL2007002620 A1 CL 2007002620A1
Authority
CL
Chile
Prior art keywords
compound
fluor
isotope
understands
kit
Prior art date
Application number
CL200702620A
Other languages
English (en)
Spanish (es)
Inventor
Lehmann Ananth Srinivasan Lutz
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06090166A external-priority patent/EP1897885A1/en
Priority claimed from EP07090079A external-priority patent/EP1985624A3/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CL2007002620A1 publication Critical patent/CL2007002620A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL200702620A 2006-09-08 2007-09-10 Compuesto marcado con isotopo de fluor; metodo para preparar dicho compuesto; composicion que comprende dicho compuesto; metodo de tomar imagenes de enfermedades que comprende el compuesto antes mencionado; kit que comprende dicho compuesto. CL2007002620A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06090166A EP1897885A1 (en) 2006-09-08 2006-09-08 Compounds and methods for F labelled agents
EP07090079A EP1985624A3 (en) 2007-04-23 2007-04-23 Single step method of radiofluorination of biologically active compounds or biomolecules

Publications (1)

Publication Number Publication Date
CL2007002620A1 true CL2007002620A1 (es) 2008-05-30

Family

ID=39031005

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702620A CL2007002620A1 (es) 2006-09-08 2007-09-10 Compuesto marcado con isotopo de fluor; metodo para preparar dicho compuesto; composicion que comprende dicho compuesto; metodo de tomar imagenes de enfermedades que comprende el compuesto antes mencionado; kit que comprende dicho compuesto.

Country Status (20)

Country Link
US (1) US8557776B2 (https=)
EP (5) EP3056509A1 (https=)
JP (2) JP5603074B2 (https=)
KR (1) KR20090058553A (https=)
AR (1) AR062726A1 (https=)
AU (1) AU2007294124A1 (https=)
BR (1) BRPI0716554A2 (https=)
CA (2) CA2662449A1 (https=)
CL (1) CL2007002620A1 (https=)
CO (1) CO6150196A2 (https=)
CR (1) CR10654A (https=)
IL (4) IL197363A0 (https=)
MA (1) MA30780B1 (https=)
MX (1) MX2009002492A (https=)
NO (1) NO20091428L (https=)
PE (1) PE20080850A1 (https=)
RU (1) RU2009112716A (https=)
TN (1) TN2009000063A1 (https=)
TW (1) TW200829277A (https=)
WO (1) WO2008028688A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009002492A (es) 2006-09-08 2009-08-28 Bayer Schering Pharma Ag Agentes que comprenden compuestos marcados con 18f y metodos relacionados.
JP2010520229A (ja) * 2007-03-01 2010-06-10 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 放射性弗素化方法
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
WO2012094334A1 (en) * 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
JP2014526952A (ja) * 2011-06-09 2014-10-09 ジーイー・ヘルスケア・リミテッド 蒸留装置及び方法
PL2970345T3 (pl) * 2013-03-15 2019-12-31 Cancer Targeted Technology Llc Znakowane 18F środki do obrazowania PET ukierunkowane na PSMA
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
US11518754B2 (en) 2017-02-17 2022-12-06 Yale University Radiolabeled pharmaceuticals and methods of making and using same
JP7325341B2 (ja) 2017-07-11 2023-08-14 シンソークス，インク． 非天然ヌクレオチドの組み込み及びその方法
KR20240141853A (ko) 2017-08-03 2024-09-27 신톡스, 인크. 자가면역 질환의 치료를 위한 사이토카인 접합체
EP3781149A4 (en) * 2018-04-20 2022-03-16 The General Hospital Corporation ACETYLATED PRODRUGS FOR ADMINISTRATION ACROSS THE BLOOD-BRAIN BARRIER
EP3923974A4 (en) 2019-02-06 2023-02-08 Synthorx, Inc. IL-2 CONJUGATES AND METHODS OF USE THEREOF
CN113150065B (zh) * 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用
US20240277876A1 (en) * 2021-05-20 2024-08-22 The Regents Of The University Of California Pet imaging tracers
KR20250164815A (ko) 2023-03-31 2025-11-25 닛산 가가쿠 가부시키가이샤 피라졸 화합물 및 유해 생물 방제제

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084555A (en) * 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
WO1989002897A1 (en) * 1987-09-24 1989-04-06 The Administrators Of The Tulane Educational Fund Therapeutic peptides
US5723578A (en) * 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
MC2144A1 (fr) * 1988-10-14 1992-02-19 Univ Tulane Peptides therapeutiques
US5342755A (en) * 1989-06-02 1994-08-30 Georgetown University Method for the detection of anti-streptokinase antibodies
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5244883A (en) 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
WO1999033792A2 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
EA200000702A1 (ru) 1997-12-24 2000-12-25 Вертекс Фармасьютикалз Инкорпорейтед Пролекарства ингибиторов аспартилпротеаз
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
US6639076B1 (en) * 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
JP2003502314A (ja) 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
WO2002044144A2 (en) * 2000-11-30 2002-06-06 Advanced Research And Technology Institute, Inc. Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds
GB0115927D0 (en) * 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
US7396846B2 (en) 2002-04-09 2008-07-08 Eli Lilly And Company Growth hormone secretagogues
WO2004018502A1 (en) * 2002-08-09 2004-03-04 Yamanouchi Europe B.V. Compounds binding to p-selectin
US20080063599A1 (en) 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
WO2004073650A2 (en) 2003-02-20 2004-09-02 University Of South Florida Peptidomimetic inhibitors of stat3 activity and their medical uses
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
WO2006083424A2 (en) 2004-12-28 2006-08-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
CA2617055A1 (en) 2005-07-29 2007-02-08 Bayer Healthcare Llc Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
US20080029548A1 (en) 2006-05-05 2008-02-07 Ann De Wree Fabric treatment dispensing package
MX2009002492A (es) 2006-09-08 2009-08-28 Bayer Schering Pharma Ag Agentes que comprenden compuestos marcados con 18f y metodos relacionados.

Also Published As

Publication number Publication date
KR20090058553A (ko) 2009-06-09
AU2007294124A1 (en) 2008-03-13
IL211033A0 (en) 2011-04-28
TW200829277A (en) 2008-07-16
EP2063918B1 (en) 2014-02-26
IL211527A0 (en) 2011-05-31
JP2010503618A (ja) 2010-02-04
JP5722966B2 (ja) 2015-05-27
EP2455105A3 (en) 2012-09-05
BRPI0716554A2 (pt) 2013-09-24
EP3056509A1 (en) 2016-08-17
EP2279759A3 (en) 2013-04-17
CR10654A (es) 2009-04-14
JP5603074B2 (ja) 2014-10-08
EP2289564A2 (en) 2011-03-02
EP2289564A3 (en) 2012-11-14
EP2279759A2 (en) 2011-02-02
MA30780B1 (fr) 2009-10-01
WO2008028688A2 (en) 2008-03-13
MX2009002492A (es) 2009-08-28
RU2009112716A (ru) 2010-10-20
NO20091428L (no) 2009-06-03
IL197363A0 (en) 2011-08-01
IL211526A0 (en) 2011-05-31
TN2009000063A1 (en) 2010-08-19
EP2455105A2 (en) 2012-05-23
CA2858907A1 (en) 2008-03-13
EP2063918A2 (en) 2009-06-03
CA2662449A1 (en) 2008-03-13
EP2455105B1 (en) 2016-02-17
JP2014028813A (ja) 2014-02-13
WO2008028688A3 (en) 2008-11-13
CO6150196A2 (es) 2010-04-20
US20080292548A1 (en) 2008-11-27
AR062726A1 (es) 2008-11-26
PE20080850A1 (es) 2008-09-02
US8557776B2 (en) 2013-10-15

Similar Documents

Publication Publication Date Title
CL2007002620A1 (es) Compuesto marcado con isotopo de fluor; metodo para preparar dicho compuesto; composicion que comprende dicho compuesto; metodo de tomar imagenes de enfermedades que comprende el compuesto antes mencionado; kit que comprende dicho compuesto.
CL2008000224A1 (es) Composicion farmaceutica que comprende un compuesto derivado glucopiranosilo; y uso para el tratamiento de uno o mas trastornos neurodegenerativos.
PL2545777T3 (pl) Zastosowanie kompozycji izoksazoliny jako środka przeciwpasożytniczego
CL2007001759A1 (es) Compuesto metformina r-(+) lipoato; mezcla que comprende metformina y acido r-(+) lipoico; composicion farmaceutica que comprende el compuesto; metodo para preparar el compuesto; kit; y uso para tratar la diabetes.
BRPI0817182A2 (pt) Método para purificar um anticorpo e composições
CL2007003202A1 (es) Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
BRPI0811720A2 (pt) Método e sistema para proporcionar plataforma personalizada para acessar aplicativo na internet através de rede social e programa de computador.
CL2007003138A1 (es) Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2007003302A1 (es) Sistema integrado de almacenamiento y entrega para composiciones nutricionales, que comprende un sello penetrable, una tapa y una punta con proyeccion la que se mueve entre los dos costados de dicho sello; metodo de uso de dicho sistema; kit que comp
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
DK1868579T3 (da) Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer
CL2007000938A1 (es) Metodo para la decodificacion de fotogramas de video que comprende la recepcion de una secuencia de video que comprende una variedad de fotogramas de video, la decodificacion de la secuencia de video y la eliminacion de uno o mas fotogramas de video
BRPI0923507A2 (pt) motor e dispositivo elétrico que usa o mesmo.
BRPI0819660A2 (pt) Método e sistema educacional que inclui pelo menos uma interface de usuário
CL2008000794A1 (es) Compuestos derivados de biarilo y heteroarilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno de hierro.
PT2347346E (pt) Método para pesquisa de conteúdo multimédia na internet
CL2007002672A1 (es) Compuesto de benceno marcado con fluor radiactivo; metodo para preparar dicho compuesto marcado; composicion que comprende dicho compuesto; metodo para diagnostico de enfermedades por imagenes; conjunto de elementos que comprende dicho compuesto; uso
CL2011001331A1 (es) Clorhidrato de nalmefeno dihidratado; métodos para su preparación; composición farmacéutica que lo comprende; y uso para el tratamiento del alcoholismo.
BRPI0910478A2 (pt) sistema e método para intensificar a visibilidade de um objeto em uma imagem digital
BRPI0815770A2 (pt) Composto de organoenxofre contendo flúor e composição pesticida do mesmo
CL2007002021A1 (es) Compuestos derivados de oxoisoindol; composicion farmaceutica que los comprende; y su uso para tratar arritmias.
BRPI0812845A2 (pt) Método para a preparação de uma composição compreendendo um absorvedor de uv orgânico insolúvel micronizado.
CL2007003041A1 (es) Compuesto inhibidor de proteina quinasa activada por mitogeno; proceso para obtener dicho compuesto; compuesto intermediario; composicion farmaceutica que comprende dicho compuesto inhibidor; kit que comprende dicho compuesto; y uso de un compuesto p
BRPI0810399A2 (pt) Composto, composição farmacêutica que o contém e uso do mesmo